EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, NOVERMBER 21, 2016
Media Advisory: To contact corresponding author Joshua I. Barzilay, M.D., call Kerri Hartsfield Johnson at 404-949-5121 or email Kerri.M.Hartsfield@kp.org.
Related material: The commentary, “Cardiovascular Medications and Fractures: Dodging Complexity,” by Cathleen S. Colón-Emeric, M.D., M.H.S., and Richard Lee, M.D., M.H.S., of the Duke University School of Medicine, Durham, N.C., also is available on the For The Media website.
To place an electronic embedded link in your story: Links will be live at the embargo time: http://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2016.6821
JAMA Internal Medicine
Further examination of randomized clinical trial data suggests that thiazide diuretics to treat hypertension may be associated with lower risk of hip and pelvic fractures compared with some other antihypertensive medications, according to an article published online by JAMA Internal Medicine.
Joshua I. Barzilay, M.D., of Kaiser Permanente of Georgia, Atlanta, and coauthors examined the effects of major classes of blood pressure-lowering medications on the incidence of hospitalization for hip and pelvic fractures.
The authors used Veterans Affairs and Medicare claims data along with data from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), a large study that compared different antihypertensive therapies to prevent fatal coronary heart disease or nonfatal heart attacks and other cardiovascular disease outcomes.
The study reports a 21 percent lower risk of hip and pelvic fractures associated with the thiazide-type diuretic chlorthalidone compared with either lisinopril (an angiotensin-converting enzyme inhibitor) or amlodipine (a calcium channel blocker).
The analyses included 22,180 participants followed for up to eight years and, after the trial was completed, 16,622 participants were followed for up to an additional five years because claims data were available for them. There were 646 hip and pelvic fractures in trial plus post trial follow-up.
In further analyses that include trial and post-trial follow-up, the fracture risk was lower in the chlorthalidone group compared with the other treatment groups, although it was not statistically significant, according to the results. During the post-trial period, the study protocol no longer constrained the choice of blood pressure medication.
The authors note several study limitations including that analyses were conducted after the trial and that the present analyses relied on databases for fracture occurrence rather than medical records.
“The present results of short-term and long-term fracture protection with thiazide antihypertensive therapy compared with other antihypertensive medications strongly recommend use of a thiazide for hypertension treatment in addition to its long track record of cardiovascular protection,” the study concludes.
(JAMA Intern Med. Published online November 21, 2016. doi:10.1001/jamainternmed.2016.6821; available pre-embargo at the For The Media website.)
Editor’s Note: The article contains conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
# # #
For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email firstname.lastname@example.org.